Alto Neuroscience (NYSE:ANRO) Rating Lowered to Sell at Wall Street Zen

Alto Neuroscience (NYSE:ANRO) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Other analysts also recently issued reports about the company. Jefferies Financial Group restated a “buy” rating and issued a $35.00 price objective on shares of Alto Neuroscience in a report on Monday. BTIG Research lifted their price objective on Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Wedbush raised their target price on Alto Neuroscience from $13.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday. Robert W. Baird upped their price target on Alto Neuroscience from $22.00 to $41.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Alto Neuroscience presently has an average rating of “Moderate Buy” and an average price target of $34.33.

Alto Neuroscience Trading Down 3.0%

NYSE ANRO opened at $21.38 on Friday. The company has a market cap of $683.04 million, a price-to-earnings ratio of -9.81 and a beta of 2.52. Alto Neuroscience has a twelve month low of $1.60 and a twelve month high of $25.17. The company has a quick ratio of 15.42, a current ratio of 15.69 and a debt-to-equity ratio of 0.12. The business’s fifty day moving average is $18.47 and its 200 day moving average is $13.60.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.11. As a group, sell-side analysts expect that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

Hedge funds have recently modified their holdings of the company. Vestal Point Capital LP lifted its holdings in Alto Neuroscience by 161.6% during the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after acquiring an additional 1,535,000 shares during the period. Commodore Capital LP bought a new position in Alto Neuroscience in the 4th quarter valued at $32,453,000. Perceptive Advisors LLC increased its position in shares of Alto Neuroscience by 1,048.5% during the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after purchasing an additional 1,629,027 shares during the last quarter. Armistice Capital LLC raised its stake in shares of Alto Neuroscience by 0.7% during the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after purchasing an additional 12,000 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Alto Neuroscience by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company’s stock worth $4,444,000 after purchasing an additional 20,702 shares during the period.

Alto Neuroscience News Summary

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Robert W. Baird raised its price target to $41, which can support upside sentiment and buying interest for growth/biotech investors. Robert W. Baird Boosts Alto Neuroscience (NYSE:ANRO) Price Target to $41.00
• Positive Sentiment: Wedbush reiterated a constructive outlook for Alto and flagged potential strong price appreciation, supporting demand from momentum/coverage-driven buyers. Wedbush Forecasts Strong Price Appreciation for Alto Neuroscience (NYSE:ANRO) Stock
• Positive Sentiment: Chardan Capital reaffirmed its Buy rating, another supportive analyst signal for investor confidence. Chardan Capital Reaffirms Buy Rating for Alto Neuroscience (NYSE:ANRO)
• Neutral Sentiment: Recent quarterly report (Mar 16) slightly beat EPS consensus, which provides some fundamental support versus the negative estimate revisions. Alto Neuroscience — Company Page
• Negative Sentiment: HC Wainwright issued a broad set of downward revisions (Mar 18) to Alto’s near- and medium-term EPS: Q1 2026 to ($0.63) from ($0.59), Q2 2026 to ($0.67) from ($0.64), Q4 2026 to ($0.74) (earlier view higher), FY2026 to ($2.75) from ($2.51), and sharper cuts to FY2027–FY2029/FY2028 (e.g., FY2028 to ($4.11) from ($2.65); FY2029 to ($2.99) from ($1.54)). These more bearish earnings trajectories increase uncertainty on cash burn and timing to profitability, which likely explains much of the downward pressure on the stock today. HC Wainwright Lowers Earnings Estimates for Alto Neuroscience

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.